Back to Market返回行情

NAUT Nautilus Biotechnology, Inc.

USHealthcare
$1.78+5.33%ClosedMarket Cap: $226.2M

As of 2026-07-08 16:00

Why NAUT matters now

Nautilus Biotechnology, Inc. (NAUT) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.78 with +5.33% on the session and $226.2M in market capitalization; recent performance reads 1-month -4.20% and YTD +16.92%.

The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-14.7M, and EPS of $-0.12. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.7%.

The latest indexable market news headline is "Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $2.50; recent insider activity includes AH Equity Partners Bio II, L.L.C. filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

2.00

P/S

0.00

EV/EBITDA

-5.99

DCF Value

$-0.15

FCF Yield

-17.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-35.0%

ROA

-32.1%

ROIC

-37.0%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$0.00$-14.7M$-0.12
Q4 2025$0.00$-13.8M$-0.11
FY 2025$0.00$-59.0M$-0.47
Q3 2025$0.00$-13.6M$-0.11

Analyst Ratings

Consensus

Buy

Target (Consensus)

$2.50

Target (Median)

$2.50

Target Range

$2.50 - $2.50

Strong Buy: 0Buy: 2Hold: 0Sell: 0Strong Sell: 0
GuggenheimBuy
2026-02-27

Trading Activity

Insider Trades

AH Equity Partners Bio II, L.L.C.10 percent owner
Sell2026-06-04
AH Equity Partners Bio II, L.L.C.10 percent owner
Sell2026-06-04
Patel Sujal Mdirector, 10 percent owner, officer: CEO, President, and Secretary
Buy2026-03-04
Suzuki Kentaroofficer: Chief Marketing Officer
Sell2026-03-04
Murphy Matthew B.officer: General Counsel
Sell2026-03-04

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

0.75

Nautilus Biotechnology, Inc. is an emerging life sciences firm dedicated to pioneering a platform technology aimed at quantifying and comprehensively understanding the intricate complexities of the proteome. Their flagship offering, the Nautilus Platform, is an integrated proteomics system. It provides a complete, end-to-end solution, including specialized instruments, essential consumables, and advanced software for data analysis. Based in Seattle, Washington, the company was established in 2016.